CV
CVS HEALTH CORP
CVSOwnership as of Q2 2026
Funds owning
12
Combined value
6.0B
Avg portfolio %
2.3%
Buys / Sells this quarter
+2 buys−8 sells
Q2-2026
| Investor | Weight | Q/Q change | Value |
|---|---|---|---|
FF Fairfax Financial Holdings – Prem Watsaas of Q1-2026 | Core 10.03% | 2.7M shares · $71.82 $194.8M | |
DS Davis Selected Advisersas of Q1-2026 | Trial 4.04% | ↘Reduced 4.08% | 12.2M shares · $71.82 $879.1M |
PC Patient Capital Managementas of Q1-2026 | Trial 3.63% | ↗Added 10.21% | 1.4M shares · $71.82 $97.5M |
HC Hillman Capital Management, Inc.as of Q1-2026 | Trial 3.36% | ↘Reduced 5.89% | 67.5K shares · $71.82 $4.8M |
PI Pzena Investment Managementas of Q1-2026 | Trial 3.21% | ↘Reduced 11.61% | 13.8M shares · $71.82 $989.2M |
D& Dodge & Coxas of Q1-2026 | Trial 2.05% | ↘Reduced 17.17% | 51.8M shares · $71.82 $3.7B |
OC Olstein Capital Management – Robert Olsteinas of Q1-2026 | Trial 0.78% | ↘Reduced 10.71% | 50.0K shares · $71.82 $3.6M |
AI Ariel Investments – John Rogersas of Q1-2026 | Trial 0.56% | ↘Reduced 14.90% | 702.2K shares · $71.82 $50.4M |
TB Tweedy Browne Coas of Q1-2026 | Trial 0.11% | ↗Added 58.31% | 19.1K shares · $71.82 $1.4M |
MA Matrix Asset Advisors – David Katz | Trial 0.05% | 6.2K shares · $103.45 $638,804 | |
HA Harris Associatesas of Q1-2026 | Trial 0.05% | ↘Reduced 5.89% | 494.1K shares · $71.82 $35.5M |
MC Maverick Capital – Lee Ainslieas of Q1-2026 | Trial 0.01% | ↘Reduced 58.23% | 9.5K shares · $71.82 $680,279 |
| 12 funds | $6.0B |